Stock Ratings / Health Care / CTY / forecast

HROW (71) MNKD (63) SPTX (56) JANX (33) ⌘ Pro Terminal →

City Therapeutics Inc. (CTY) 12-Month Stock Forecast & Price Target Cone

$22.14 +2.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

City Therapeutics Inc. (CTY) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $1.11B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTY)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CTY Position Size: $10,000

Shares at $22.14: 451.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $17.50

$7,904

$-2,096 (-21.0%)

12M Consensus BaseTarget $22.44

$10,136

+$136 (+1.4%)

12M Bull Case BreakoutTarget $26.48

$11,960

+$1,960 (+19.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$23	74%	A
Goldman SachsSector Coverage Lead	BUY	$25	69%	B
JP MorganUS Large-Cap Research	HOLD	$20	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CTY Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CTY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.16%

2026-10-30O $22.08H $22.26L $20.37C $22.14VOL 116.8K

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTY Butterfly Map → + Track CTY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CTY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CTY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTY)

Health Care Rank #187 of 1016 ⚔️ HROW vs CTY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTY vs. HROW, MNKD, SPTX, JANX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, City Therapeutics Inc. (CTY) ranks #187 by composite RQD confidence (61/100, grade C-) and #350 by equity capitalization ($1.11B). Within this direct 5-issuer industry benchmark cohort, CTY leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with CTY at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CTY ACTIVE City Therapeutics Inc.	C-	61/100	—	—	—	+2.26%	$1.11B	Benchmark Subject
HROW Harrow Inc.	B-	71/100	—	75.1%	42.9%	+2.04%	$1.12B	/hrow-vs-cty →
MNKD MannKind Corporation	C	63/100	—	92.3%	54.5%	+2.04%	$1.13B	/mnkd-vs-cty →
SPTX Seaport Therapeutics Inc.	D+	56/100	—	—	—	+3.53%	$1.13B	/sptx-vs-cty →
JANX Janux Therapeutics Inc.	E	33/100	—	—	-13.8%	-1.22%	$1.09B	/janx-vs-cty →

2. CTY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

City Therapeutics Inc. (CTY) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.11B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. CTY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, City Therapeutics Inc. (NASDAQ: CTY) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $22.14 (+2.26% 1D, market cap $1.11B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CTY ranks #187 in composite RQD confidence.

How does CTY compare to HROW and MNKD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTY carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, HROW (Harrow Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC 42.9%, cap $1.12B) and MNKD (MannKind Corporation) posts a C grade (63/100 RQD, P/E N/A, ROIC 54.5%, cap $1.13B). Among the 5-stock peer group, CTY leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTY?

For City Therapeutics Inc. (CTY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #187 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTY trading relative to its 50-day, 200-day, and 52-week technical levels?

CTY last traded at $22.14 (+2.26% on volume of 130,928 shares), positioning the stock +1.84% above its 50-day simple moving average ($21.74) and +5.48% above its 200-day simple moving average ($20.99). Across its 52-week range of $19.75 to $23.88, CTY sits at the 57.9% percentile with a 14-day RSI of 61.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($19.37 to $24.91).

CTY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CTY's 12-month stock price target?

City Therapeutics Inc. (CTY) carries a 12-month consensus base price target of $22.44 (+1.4% from $22.14), with a bull-case target of $26.48 and a bear-case floor of $17.5.

Is CTY stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates CTY C- (Hold — HOLD) with an RQD Confidence score of 61/100.

Direct Sub-Reports: CTY RQD Cockpit CTY 12M Forecast CTY Earnings & Move CTY Dividends & DRIP CTY Insiders & 13F CTY Whale Options CTY Profit Sankey CTY News & Why